HOME > INVESTOR > ARCHIVES > PRESS RELEASE
December 2017
Lupin receives FDA appLupin receives FDA approval for generic Dovonex Scalp Solution
Date: December 28
Lupin receives FDA approval for generic Safyral Tablets
Date: December 14
November 2017
Letter to the exchange regading the warning letter issued by USFDA
Date: November 8
Lupin launches generic Acticlate® Tablets in the US
Date: November 2
October 2017
Lupin Quarter II, FY2018 - Results
Date: October 30
Intimation to the Exchanges on Investors Call
Date: October 27
Lupin receives FDA approval for generic Kapvay® Extended-Release Tablets
Date: October 26
Lupin receives FDA approval for generic Axiron® topical solution
Date: October 25
Lupin receives FDA approval for generic Lodosyn® tablets
Date: October 24
Notice to the Exchanges on Board Meeting
Date: October 12
Lupin Acquires Symbiomix Therapeutics LLC
Date: October 11
Lupin launches generic Norco® tablets in the US
Date: October 10
Lupin receives FDA approval for generic Corgard® Tablets
Date: October 09
September 2017
Lupin receives FDA approval for generic Acticlate® Tablets
Date: September 29
Lupin receives FDA approval for generic Clobex® Lotion
Date: September 25
Lupin appoints Jim Loerop as Chief Corporate Development Officer
Date: September 18
Lupin receives FDA approval for generic Flagyl® Tablets
Date: September 13
Lupin receives FDA approval for generic Vibra-Tabs® Tablet
Date: September 11
Lupin launches generic Benicar® tablets in the US
Date: September 4
August 2017
Lupin launches generic Fosrenol Chewable Tablets in the US
Date: August 31
NHI Drug Price Listing for Bipresso® Extended Release Tablets for the Improvement of Depressive Symptoms Associated with Bipolar Disorder Announced
Date: August 30
Lupin launches generic Seroquel XR® tablets in the US
Date: August 23
Lupin receives EIR from US FDA for Aurangabad, April 2017 Inspection
Date: August 21
Lupin’s alliance partner Natco receives FDA approval for generic Fosrenol Chewable Tablets
Date: August 14
Lupin appoints Mrs. Manju Deshbandhu Gupta as Chairman
Date: August 11
Lupin receives FDA approval for Nikita™ (Pitavastatin) Tablets
Date: August 9
Lupin receives FDA approval for generic Crestor® tablets
Date: August 3
Quarter I, FY2018 - Results
Date: August 2
Lupin receives FDA approval for generic Lidex® Ointment
Date: August 1
July 2017
Lupin’s Aurangabad facility inspection concluded by US FDA
Date: July 31
Lupin’s Pithampur facility inspection concluded by US FDA without any observations
Date: July 28
Lupin receives FDA approval for Fluocinonide Topical Solution
Date: July 24
Lupin’s Goa facility inspection concluded by US FDA without any observations
Date: July 21
Notice to the Exchanges on Board Meeting
Date: July 18
American Academy of Ophthalmology and Lupin Collaborate to Enhance Continuing Ophthalmic Medical Education in India
Date: July 11
Lupin receives FDA approval for generic Ancobon® Capsules
Date: July 10
Lupin launches generic Vigamox® Ophthalmic solution in the US
Date: July 07
June 2017
Dr. Desh Bandhu Gupta, Founder and Chairman of Lupin passes away
Date: June 26
Lupin launches generic Topicort® LP Emollient Cream and Topicort® Cream in the US
Date: June 22
Lupin launches generic Wellbutrin XL® Tablets in the US
Date: June 15
Lupin receives FDA approval for generic Roxicodone® Tablets
Date: June 14
May 2017
Quarter IV and Annual Results, FY2017
Date: May 24
Lupin receives approval for Bepotastine Tablets - a new second generation Antihistamine
Date: May 22
Lupin receives FDA approval for generic Seroquel XR® Tablets
Date: May 18
Lupin and Lilly Expand Partnership in India
Date: May 16
Notice to the Exchanges on Annual Investor Meet
Date: May 10
Notice to the Exchanges on Board Meetings
Date: May 03
April 2017
Lupin receives FDA approval for generic Benicar® Tablets
Date: April 28
Lupin receives FDA approval for generic Wellbutrin XL® Tablets
Date: April 08
March 2017
Lupin launches Generic Epzicom® tablets in the US
Date: March 29
Lupin Receives FDA Approval for Generic TOBI® Inhalation Solution
Date: March 23
Lupin launches Generic Minastrin® 24 Fe chewable tablets in the US
Date: March 16
Lupin launches Hydrocodone Bitartrate and Acetaminophen tablets in the US
Date: March 09
Lupin launches Generic Paxil CR® tablets in the US
Date: March 07
Lupin Receives FDA Approval for Generic Suprep® Bowel Prep Kit
Date: March 03
Lupin Launches Generic Pristiq® Tablets in the US
Date: March 02
Lupin Launches Generic Temovate® Clobetasol Propionate Scalp Application in the US
Date: March 01
February 2017
Lupin Receives FDA Approval for Generic Percocet® Tablets
Date: February 28
Astellas and Lupin’s subsidiary Kyowa enter into an Agreement
Date: February 27
Disclosure to the Exchanges regarding the USFDA approval for ANDA Moxifloxacin Hydrochloride Tablets
Date: February 16
Disclosure to the Exchanges regarding the USFDA approval for ANDA Hydrocodone Bitartrate and Homatropine Methylbromide Oral Solution
Date: February 16
Lupin Quarter III Results, FY2017
Date: February 09
Lupin Receives FDA Approval for Triamcinolone Acetonide Cream
Date: February 03
January 2017
Lupin Launches Generic Ortho-Cyclen® 28 Tablets in the US
Date: January 24
Notice to the Exchanges on Board Meetings
Date: January 23
Lupin Receives FDA Approval for Generic Paxil CR® Tablets
Date: January 23
Lupin Launches Generic MS Contin® ER Tablets in the US
Date: January 13
Lupin Receives FDA Approval for Generic Topicort® LP Emollient Cream, 0.05% and Topicort® Cream, 0.25%
Date: January 11
Lupin Receives FDA Approval for Generic Evoxac® Capsules
Date: January 02